Boston Scientific (NYSE:BSX) Raised to "Outperform" at Oppenheimer

Key Points

• Boston Scientific's stock was upgraded by Oppenheimer from a "market perform" rating to an "outperform" rating, with a price target set at $125.00, indicating a potential upside of 16.67%.
• The company reported a quarterly earnings per share (EPS) of $0.75, exceeding analysts' expectations and demonstrating a revenue increase of 22.8% year-over-year.
• Institutional investors own 89.07% of Boston Scientific's stock, reflecting strong interest from larger investment firms.

Boston Scientific (NYSE:BSX - Get Free Report) was upgraded by stock analysts at Oppenheimer from a "market perform" rating to an "outperform" rating in a research report issued to clients and investors on Monday, MarketBeat.com reports. The firm currently has a $125.00 price target on the medical equipment provider's stock, up from their prior price target of $118.00. Oppenheimer's target price indicates a potential upside of 21.70% from the company's current price.

A number of other analysts have also recently issued reports on the company. UBS Group raised their price objective on Boston Scientific from $130.00 to $135.00 and gave the company a "buy" rating in a research report on Thursday, July 24th. Barclays lifted their price target on Boston Scientific from $125.00 to $133.00 and gave the stock an "overweight" rating in a report on Thursday, July 24th. Wells Fargo & Company lifted their price target on Boston Scientific from $118.00 to $124.00 and gave the stock an "overweight" rating in a report on Thursday, July 24th. Leerink Partners began coverage on Boston Scientific in a research note on Monday, June 16th. They set an "outperform" rating and a $118.00 price objective on the stock. Finally, Morgan Stanley raised their price objective on Boston Scientific from $120.00 to $125.00 and gave the stock an "overweight" rating in a research note on Friday, May 16th. Three analysts have rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and one has assigned a Hold rating to the company's stock. According to data from MarketBeat, Boston Scientific currently has an average rating of "Buy" and a consensus target price of $118.04.

Boston Scientific Stock Performance

Shares of BSX traded down $1.63 during mid-day trading on Monday, reaching $102.71. The company's stock had a trading volume of 10,541,837 shares, compared to its average volume of 6,118,901. Boston Scientific has a 1-year low of $80.64 and a 1-year high of $109.50. The stock has a market cap of $152.19 billion, a P/E ratio of 61.14, a PEG ratio of 2.51 and a beta of 0.65. The business has a 50-day simple moving average of $104.86 and a two-hundred day simple moving average of $102.26. The company has a current ratio of 1.37, a quick ratio of 0.82 and a debt-to-equity ratio of 0.49.

Boston Scientific (NYSE:BSX - Get Free Report) last released its quarterly earnings data on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.72 by $0.03. Boston Scientific had a return on equity of 19.21% and a net margin of 13.55%.The company had revenue of $5.06 billion during the quarter, compared to analysts' expectations of $4.89 billion. During the same period last year, the firm posted $0.62 earnings per share. The business's revenue was up 22.8% on a year-over-year basis. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. As a group, equities research analysts anticipate that Boston Scientific will post 2.85 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Boston Scientific news, Director Yoshiaki Fujimori sold 2,901 shares of the company's stock in a transaction dated Tuesday, July 29th. The stock was sold at an average price of $106.99, for a total value of $310,377.99. Following the sale, the director owned 2,081 shares in the company, valued at approximately $222,646.19. The trade was a 58.23% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Joseph Michael Fitzgerald sold 50,000 shares of the company's stock in a transaction dated Tuesday, September 2nd. The shares were sold at an average price of $105.43, for a total value of $5,271,500.00. Following the completion of the sale, the executive vice president owned 178,342 shares in the company, valued at $18,802,597.06. This trade represents a 21.90% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 174,214 shares of company stock worth $18,397,457. Corporate insiders own 0.50% of the company's stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in BSX. Norges Bank acquired a new position in shares of Boston Scientific in the 2nd quarter valued at about $2,089,937,000. Edgewood Management LLC acquired a new position in Boston Scientific during the 2nd quarter worth approximately $746,655,000. Bessemer Group Inc. raised its stake in Boston Scientific by 14,391.8% during the 2nd quarter. Bessemer Group Inc. now owns 2,919,801 shares of the medical equipment provider's stock worth $313,618,000 after buying an additional 2,899,653 shares during the period. GAMMA Investing LLC raised its stake in Boston Scientific by 11,720.3% during the 1st quarter. GAMMA Investing LLC now owns 2,577,887 shares of the medical equipment provider's stock worth $260,057,000 after buying an additional 2,556,078 shares during the period. Finally, Vanguard Group Inc. raised its stake in Boston Scientific by 1.9% during the 2nd quarter. Vanguard Group Inc. now owns 137,134,110 shares of the medical equipment provider's stock worth $14,729,575,000 after buying an additional 2,545,381 shares during the period. 89.07% of the stock is owned by institutional investors and hedge funds.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.